Drug ID: 2d00000018
Drug Name: Bendamustine hydrochloride
Generic Names: Mustin (100mg) | Treanda
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The recommended dose is 100 mg/m² over 30 minutes infusion on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
Recommended In: This medication is an alkylating agent, prescribed for chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL). It kills existing cancer cells and limits new cancer cells growth.
Directions For Use: It comes as a solution for injection to be administered by a healthcare provider into the vein.
Storage: Store it in room temperature (25°C).
Dosage Forms: Intravenous Injection
Side Effects: Most Common - Fever, nausea and vomiting, weakness, fatigue, uneasiness, dry mouth, drowsiness, cough, constipation, headache and mouth ulcer.
Heart - Fast heart rate and low blood pressure.
Gastrointestinal - Nausea, vomiting, diarrhea, constipation, mouth ulcer, abdominal pain, indigestion, gastroesophageal reflux disease and dry mouth.
General - Fatigue, fever, chills, swelling in the extremities, weakness, infections, chest pain and injection site pain.
Metabolic - Loss of appetite, dehydration, decreased potassium level in blood and decrease in weight.
Musculoskeletal - Back pain, joint pain, pain in extremity and bone pain.
Central Nervous system - Headache, dizziness, sensory loss, sleeplessness, anxiety and depression.
Respiratory - Cough, difficulty in breathing, wheezing and nose congestion.
Skin - Rash, itching, dry skin, night sweats and acidity.
In Case of Overdose: Toxicities included sedation, tremor, ataxia, convulsions and respiratory distress. No specific antidote for Bendamustine hydrochloride overdose is known. Management of overdosage should include general supportive measures, including monitoring of hematologic parameters and ECGs.
Avoid If: Contraindicated in patients with severe kidney disease, and hypersensitivity.
Caution should be exercised in patients with history of infection, liver or kidney problems, other types of cancer, bone marrow depression, any allergy, who are taking this medications, children during pregnancy and breastfeeding.
It may cause drowsiness or dizziness, do not drive a car or operate machinery while taking this medication.
It may reduce platelet counts; avoid injury or bruising.
Avoid contact with people who have infections.
Avoid live vaccinations during the treatment period.
Monitor liver, kidney function, uric acid level, complete blood count, blood chemistry regularly while taking this medication.
Drug Interaction: Bendamustine's active metabolites, gamma-hydroxy bendamustine (M3) and N-desmethyl-bendamustine (M4), are formed via cytochrome P450 CYP1A2. Inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin) have potential to increase plasma concentrations of bendamustine and decrease plasma concentrations of active metabolites. Inducers of CYP1A2 (e.g., omeprazole, smoking) have potential to decrease plasma concentrations of bendamustine and increase plasma concentrations of its active metabolites. Caution should be used, or alternative treatments considered if concomitant treatment with CYP1A2 inhibitors or inducers is needed.